Impax announces FDA approval of follow-on sevelamer carbonate

Fármacos complejos no biológicos/ Novedades | Posted 17/11/2017 post-comment0 Post your comment

US generics maker Impax Laboratories (Impax) announced on 23 October 2017 that it had received final US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) for a follow-on version of Renvela (sevelamer carbonate).

Nanoparticle V13J18

Sevelamer is classified as a non-biological complex drug (NBCD), but since there are currently no guidelines for ‘follow-on’ versions of NBCDs, such drugs are approved under the generics or hybrid pathways. However, due to their complexity and the fact that they cannot be fully quantitated, characterized or described by (physico)chemical analytical tools, some groups have said that the generics and hybrid pathways for these products may not be appropriate, and have called for regulatory guidelines for follow-on versions of NBCDs [1].

The originator product Sanofi’s Renvela (sevelamer carbonate) is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Sevelamer carbonate tablets had US brand name and follow-on version sales of approximately US$1.9 billion, according to IMS Health for the 12 months ending August 2017.

Impax has gained approval for its follow-on version of the tablets at a dosage of 800 mg and says that it ‘has immediately initiated commercialization activities’.

Follow-on versions of sevelamer carbonate tablets 800 mg were also approved by FDA from Aurobindo Pharma and Dr Reddy’s Laboratories in July and September 2017, respectively.

Related articles
Amneal and Impax combine to create 5th largest US generics company

FDA approves follow-on version of sevelamer

In vitro analysis of follow-on versions of sevelamer

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Guidelines needed for follow-on versions of NBCDs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2017 Nov 17]. Available from: www.gabionline.net/Reports/Guidelines-needed-for-follow-on-versions-of-NBCDs

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

Source: US FDA, Impax

comment icon Comments (0)
Post your comment
Related content
FDA approves 40 mg follow-on version of glatiramer acetate
NBCD ASEAN V16F09BF S69 V16F20JM
Fármacos complejos no biológicos/ Novedades Posted 09/03/2018
Mylan launches first follow-on glatiramer acetate in the UK
Multiple Sclerosis V14A24
Fármacos complejos no biológicos/ Novedades Posted 15/02/2018
FDA approves follow-on version of sevelamer
99 AA010633
Fármacos complejos no biológicos/ Novedades Posted 30/06/2017
Warning letter causes delays for follow-on glatiramer acetate
Multiple Sclerosis V14A24
Fármacos complejos no biológicos/ Novedades Posted 17/03/2017
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010